Blue Cross NCCommercial · Coverage · Medical Policy · NC · Gastroenterology, Infectious Disease, Internal Medicine +1 moreHigh impact
Medical Policy Update December 10, 2025
Act
immediately
Effective date
Dec 10, 2025
Identified
Jun 16, 2026
Summary
Blue Cross Blue Shield of North Carolina updated multiple medical policies effective December 10, 2025, with significant changes to hepatitis testing coverage (adding HCPCS G0567 and expanding immunocompromised patient criteria), nucleic acid probe testing (removing several direct probe tests from coverage), and pancreatic enzyme testing (removing amylase coverage for most indications).
Get alerts when payers change rules like this one
We check Blue Cross NC and other payers every day and email you when a change matches your specialty and state.
01Update billing system to include new HCPCS code G0567 for hepatitis testing in immunocompromised patients.
02Stop billing codes 87480, 87481, and 87482 for direct probe nucleic acid testing - these are now non-covered.
03Remove serum amylase testing from most pancreatic enzyme panels except for pancreatic cyst fluid analysis.
04Update encounter forms and provider documentation requirements for hepatitis testing frequency changes (HCV antibody testing now every 3 months for high-risk patients).
If missed: Failure to comply will result in claim denials.
Codes mentioned
G0567874808748187482
Original notice
Medical Policy Update December 10, 2025
bluecrossnc.com · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.